Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

Afsar, Cıgdem; Karabulut, Mehmet; Karabulut, Senem; Alis, Halil; Gonenc, Murat; Dagoglu, Nergiz; Serilmez, Murat; Tas, Faruk

doi:10.1016/j.jiac.2016.12.003

Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma

Atıf İçin Kopyala

Afsar C. U., Karabulut M., Karabulut S., Alis H., Gonenc M., Dagoglu N., ...Daha Fazla

JOURNAL OF INFECTION AND CHEMOTHERAPY, cilt.23, ss.196-200, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 23
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.jiac.2016.12.003
Dergi Adı: JOURNAL OF INFECTION AND CHEMOTHERAPY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.196-200
Anahtar Kelimeler: IL-18, Diagnostic, Pancreatic adenocarcinoma, Predictive, Serum, CANCER, METASTASIS, EXPRESSION
İstanbul Üniversitesi Adresli: Evet

Özet

Background: This study was conducted to investigate the serum levels of interleukin-18 (IL-18) in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters.